Quantcast
Last updated on April 19, 2014 at 5:20 EDT

Latest Certolizumab pegol Stories

2008-10-06 09:00:09

ORLANDO, Fla., Oct. 6 /PRNewswire/ -- UCB today presented data from a large, prospective study investigating endoscopic improvement in Crohn's disease (CD) with a biologic compound. The data presented at the American College of Gastroenterology Annual Scientific Meeting demonstrates that CIMZIA(R) (certolizumab pegol) -- the only PEGylated anti-TNF alpha (Tumor Necrosis Factor alpha) -- significantly improved endoscopic lesions and induced endoscopic response (as assessed by the Crohn's...

2008-07-07 06:00:26

UCB's certolizumab is marketed under the brand name Cimzia. The submission for rheumatoid arthritis treatment, if accepted, will make it the first and only PEGylated, Fc-Free anti-TNF (tumor necrosis factor) alpha biologic therapy in Europe. Certolizumab has some advantages over current treatments but its late arrival on the market will work against it as it tries to claim market share. UCB announced on July 1, 2008 that a Marketing Authorization Application (MAA) has been submitted to the...

2008-07-01 03:00:09

The European marketing authorisation application for Cimzia(R) has been filed. Subject to approval, Cimzia(R) will be the first and only PEGylated, Fc-Free anti-TNF (Tumour Necrosis Factor alpha) biologic therapy. BRUSSELS, BELGIUM - July 1st 2008 - 7:00 am CET - UCB today announced that a Marketing Authorisation Application (MAA) has been submitted to the European Medicines Agency (EMEA) requesting the approval of Cimzia(R) (certolizumab pegol) as a subcutaneous treatment for adults with...

2005-10-18 09:02:44

LONDON (Reuters) - UCB's experimental drug Cimzia is effective and well-tolerated in treating Crohn's disease, a chronic inflammatory disorder of the digestive tract, researchers said on Tuesday. The Belgian drug maker said it now planned to file the drug for regulatory approval in both the United States and Europe during the first quarter of 2006. Cimzia, or CDP870, is a key product from UCB, which is seeking new sources of sales growth ahead of the loss of U.S. patent protection...